Rademikibart (CBP-201)
Moderate-to-Severe Atopic Dermatitis
Key Facts
About Connect Biopharma
Connect Biopharma's mission is to develop best-in-class therapies for immune-mediated diseases with significant unmet need, focusing on chronic inflammatory conditions like atopic dermatitis, asthma, and inflammatory bowel disease. Its key achievement is advancing rademikibart (CBP-201) into global Phase 3 trials for atopic dermatitis, generating promising efficacy and safety data. The company's strategy involves capital-efficient, data-driven clinical development across major markets (US, China, EU) to create partnership and commercialization opportunities. With a public listing on NASDAQ, Connect aims to translate its clinical pipeline into validated treatments and strategic value.
View full company profileAbout Connect Biopharma
Connect Biopharma's mission is to develop best-in-class therapies for immune-mediated diseases with significant unmet need, focusing on chronic inflammatory conditions like atopic dermatitis, asthma, and inflammatory bowel disease. Its key achievement is advancing rademikibart (CBP-201) into global Phase 3 trials for atopic dermatitis, generating promising efficacy and safety data. The company's strategy involves capital-efficient, data-driven clinical development across major markets (US, China, EU) to create partnership and commercialization opportunities. With a public listing on NASDAQ, Connect aims to translate its clinical pipeline into validated treatments and strategic value.
View full company profileTherapeutic Areas
Other Moderate-to-Severe Atopic Dermatitis Drugs
| Drug | Company | Phase |
|---|---|---|
| Lebrikizumab | Eli Lilly | Regulatory Review |
| Amlitelimab | Sanofi | Phase 3 |
| Zumilokibart (APG777) | Apogee Therapeutics | Phase 2 |
| APG279 (Zumilokibart + APG990) | Apogee Therapeutics | Phase 1 |
| Ebglyss/Lebrikizumab | Almirall | Marketed/Registration |
| IDgenix (AdvanceAD Tx) | Castle Biosciences | Commercial/Early Launch |